Recent clinical data surrounding Retatrutide , specifically the 120 milligram formulation branded as ZPHC, suggest a significant impact on body mass decrease and linked metabolic factors. Scientists anticipate that this dual agonist , affecting both GLP-1 and GIP pathways , has the potential to p